Core One Labs Inc. (CLABF)
USD 0.04
(-10.28%)
USD 0.04
(-10.28%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -7.83 Million CAD | 35.62% |
| 2021 | -12.17 Million CAD | -86.68% |
| 2020 | -6.52 Million CAD | 57.48% |
| 2019 | -15.33 Million CAD | -28.67% |
| 2018 | -11.92 Million CAD | 8.14% |
| 2017 | -12.97 Million CAD | -568.75% |
| 2016 | -1.94 Million CAD | -80.78% |
| 2015 | -1.07 Million CAD | -149.54% |
| 2014 | -430.16 Thousand CAD | 12.58% |
| 2013 | -492.07 Thousand CAD | -7.13% |
| 2012 | -459.33 Thousand CAD | -76.49% |
| 2011 | -260.26 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q1 | -3.04 Million CAD | -38.18% |
| 2023 Q2 | -384.51 Thousand CAD | 87.38% |
| 2023 Q3 | -1.24 Million CAD | -223.12% |
| 2022 FY | -7.83 Million CAD | 35.62% |
| 2022 Q4 | -2.2 Million CAD | -102.56% |
| 2022 Q1 | -3.19 Million CAD | 86.92% |
| 2022 Q2 | -1.49 Million CAD | 53.13% |
| 2022 Q3 | -1.08 Million CAD | 27.21% |
| 2021 FY | -12.17 Million CAD | -86.68% |
| 2021 Q1 | -7.96 Million CAD | -1649.19% |
| 2021 Q2 | 1.59 Million CAD | 120.04% |
| 2021 Q3 | 2.48 Million CAD | 55.48% |
| 2021 Q4 | -24.4 Million CAD | -1083.29% |
| 2020 Q2 | -326.27 Thousand CAD | 68.43% |
| 2020 Q3 | -2.75 Million CAD | -744.2% |
| 2020 Q4 | -455.44 Thousand CAD | 83.46% |
| 2020 FY | -6.52 Million CAD | 57.48% |
| 2020 Q1 | -1.03 Million CAD | 85.0% |
| 2019 Q2 | -2.84 Million CAD | -0.17% |
| 2019 FY | -15.33 Million CAD | -28.67% |
| 2019 Q4 | -6.88 Million CAD | -148.44% |
| 2019 Q1 | -2.83 Million CAD | 13.04% |
| 2019 Q3 | -2.77 Million CAD | 2.4% |
| 2018 Q4 | -3.26 Million CAD | 11.5% |
| 2018 FY | -11.92 Million CAD | 8.14% |
| 2018 Q2 | -2.85 Million CAD | -34.33% |
| 2018 Q1 | -2.12 Million CAD | 69.31% |
| 2018 Q3 | -3.68 Million CAD | -29.25% |
| 2017 Q2 | -891.04 Thousand CAD | -53.29% |
| 2017 Q1 | -581.29 Thousand CAD | -11.13% |
| 2017 Q4 | -6.91 Million CAD | -72.8% |
| 2017 FY | -12.97 Million CAD | -568.75% |
| 2017 Q3 | -4 Million CAD | -349.21% |
| 2016 Q2 | -359.15 Thousand CAD | -5.2% |
| 2016 Q3 | -716.89 Thousand CAD | -99.61% |
| 2016 Q4 | -523.09 Thousand CAD | 27.03% |
| 2016 FY | -1.94 Million CAD | -80.78% |
| 2016 Q1 | -341.41 Thousand CAD | -27.81% |
| 2015 Q2 | -344.69 Thousand CAD | -179.12% |
| 2015 Q4 | -267.13 Thousand CAD | 20.99% |
| 2015 Q3 | -338.11 Thousand CAD | 1.91% |
| 2015 FY | -1.07 Million CAD | -149.54% |
| 2015 Q1 | -123.49 Thousand CAD | 47.23% |
| 2014 Q3 | -102.6 Thousand CAD | -179.62% |
| 2014 Q1 | -56.87 Thousand CAD | 52.98% |
| 2014 Q2 | -36.69 Thousand CAD | 35.48% |
| 2014 FY | -430.16 Thousand CAD | 12.58% |
| 2014 Q4 | -234 Thousand CAD | -128.07% |
| 2013 Q2 | -213.48 Thousand CAD | -190.06% |
| 2013 FY | -492.07 Thousand CAD | -7.13% |
| 2013 Q1 | -73.59 Thousand CAD | 1.29% |
| 2013 Q3 | -84.05 Thousand CAD | 60.63% |
| 2013 Q4 | -120.94 Thousand CAD | -43.89% |
| 2012 Q3 | -74.29 Thousand CAD | 13.01% |
| 2012 Q1 | -225.07 Thousand CAD | -1543.14% |
| 2012 FY | -459.33 Thousand CAD | -76.49% |
| 2012 Q2 | -85.4 Thousand CAD | 62.06% |
| 2012 Q4 | -74.56 Thousand CAD | -0.36% |
| 2011 FY | -260.26 Thousand CAD | 0.0% |
| 2011 Q1 | -35.87 Thousand CAD | 0.0% |
| 2011 Q2 | -42.36 Thousand CAD | -18.11% |
| 2011 Q3 | -168.33 Thousand CAD | -297.32% |
| 2011 Q4 | -13.69 Thousand CAD | 91.86% |
| 2010 Q3 | -14.00 CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.16 Million USD | -147.37% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -741.479% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -198.28% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 56.086% |
| GB Sciences, Inc. | -1.42 Million USD | -451.73% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -130.174% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -3461.178% |
| Skye Bioscience, Inc. | -13.67 Million USD | 42.675% |
| Zenith Capital Corp. | -8.94 Million USD | 12.363% |
| Agentix Corp. | -1.37 Million USD | -471.338% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -55.365% |
| Biomind Labs Inc. | -1 Million USD | -676.282% |
| ContraFect Corporation | -56.88 Million USD | 86.223% |
| CSL Limited | 3.7 Billion USD | 100.212% |
| CytoDyn Inc. | -18.05 Million USD | 56.599% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -320.376% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -1911.8% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 85.881% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1786.346% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -410.229% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1040.894% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 109.575% |
| SQZ Biotechnologies Company | -75.82 Million USD | 89.664% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -294.536% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 89.082% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -174.947% |
| Mesoblast Limited | -84.14 Million USD | 90.686% |
| Marizyme, Inc. | -34.08 Million USD | 77.007% |
| Genus plc | 6.4 Million USD | 222.459% |
| Pharming Group N.V. | -4.87 Million USD | -60.617% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 6.139% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -459.017% |
| IMV Inc. | -38.67 Million USD | 79.733% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -184.908% |
| MultiCell Technologies, Inc. | -722.81 USD | -1084191.861% |
| ONE Bio Corp. | 13.68 Million USD | 157.284% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 86.714% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 321.395% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -170.138% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -17.89% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -26066.433% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 50.614% |
| Alpha Cognition Inc. | -9.7 Million USD | 19.249% |
| Enzolytics Inc. | -2.14 Million USD | -264.732% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 98.156% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -650.706% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -168.454% |
| Genscript Biotech Corporation | -415.79 Million USD | 98.115% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 259.464% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -2894.494% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -219.2% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -4469.641% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -290.939% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 180.446% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -72.071% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -109.196% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -696.438% |
| EV Biologics, Inc. | -483.06 Thousand USD | -1522.436% |
| Q BioMed Inc. | -3.44 Million USD | -127.459% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -523.994% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 85.743% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | -0.751% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -305.533% |
| HST Global, Inc. | -140.9 Thousand USD | -5462.087% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -486.879% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -596.713% |
| Halberd Corporation | -75.05 Thousand USD | -10342.865% |
| Resverlogix Corp. | -12.74 Million USD | 38.526% |
| Cell Source, Inc. | -4.32 Million USD | -81.196% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -396.239% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 6.69 Million USD | 217.1% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -44888.06% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -2.46 Million USD | -217.719% |
| Kadimastem Ltd | -3.04 Million USD | -157.787% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -84.913% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -4218.467% |
| LadRx Corporation | -3.82 Million USD | -104.972% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1040.894% |
| Affymax, Inc. | -15.04 Million USD | 47.911% |
| Itoco Inc. | -919.14 Thousand USD | -752.685% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -600.391% |
| Mobile Lads Corp. | -554.55 Thousand USD | -1313.285% |
| International Stem Cell Corporation | -663 Thousand USD | -1082.107% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -3.82 Million USD | -105.159% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -31037.743% |
| Qrons Inc. | -643.67 Thousand USD | -1117.594% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -1287.826% |
| SYBLEU INC | -149.18 Thousand USD | -5153.633% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -251.471% |
| Rebus Holdings, Inc. | -664 Thousand USD | -1080.327% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -331.497% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -14788.621% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -38431.809% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 78.389% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -384.386% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -965.099% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -151.924% |
| Neutra Corp. | -229.48 Thousand USD | -3315.184% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 55.315% |
| PureTech Health plc | -146.19 Million USD | 94.639% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 63.532% |
| IXICO plc | -1.43 Million USD | -445.398% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 17.423% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 93.566% |
| CSL Limited | 3.81 Billion USD | 100.206% |
| Cellectis S.A. | -108.85 Million USD | 92.8% |